Kang
YK
et al.
Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomized, double-blind, placebo controlled, phase 3 trial. Lancet. 2017 Dec 2;390(10111):2461–71.
[PubMed: 28993052]